{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:08:12Z","timestamp":1793236092996,"version":"4.5.0"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Trastuzumab is a humanized HER2 targeting monoclonal antibody, and it is indicated for the treatment of various HER-2-positive cancers, including breast and gastrointestinal cancers. The standard protocol involves a 90-min intravenous loading dose, followed by 30-min maintenance infusions. If a maintenance dose is missed by more than a week, the prescribing information recommends a 90-min reloading infusion of 8\u2005mg\/kg, regardless of prior tolerance and duration of maintenance therapies. This study aims to assess the safety of 30-min reloading infusions which has not been previously studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center, retrospective cohort study that compared the safety of trastuzumab reloading 8\u2005mg\/kg as 30\u2005min infusion and 90\u2005min infusion in adults with HER2-positive cancers at a comprehensive cancer center. The primary endpoint was the incidence of infusion-related reactions (IRRs). Secondary endpoints included IRR severity, number of symptoms, time to reaction, rate of decrease in left ventricular ejection fraction (LVEF), and IRR risk factor identification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 169 patients were included (90-min = 123; 30-min = 46). Our findings demonstrated that the shorter 30\u2005min infusion is as safe as 90\u2005min infusion. The IRR rate was 0% in 30\u2005min vs. 4% in 90\u2005min. Additionally, the mean percentage of LVEF reduction was similar between the two cohorts (4.1% in 30\u2005min vs. 3.97% in 90\u2005min; P\u2009=\u20090.99).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Trastuzumab reloading doses can be safely administered as a 30-min infusion, without increased risk of IRR or cardiotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261491928","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:40:05Z","timestamp":1790354405000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility and safety of 30-minute Trastuzumab reloading infusion in patients with HER2-positive solid tumors"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1619-4266","authenticated-orcid":false,"given":"Shemroy","family":"McCarthy","sequence":"first","affiliation":[{"name":"Northwell Health Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Harris","family":"Jalili","sequence":"additional","affiliation":[{"name":"Northwell Health Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara S","family":"Kim","sequence":"additional","affiliation":[{"name":"Northwell Health Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2174\/1871520622666220302114313"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275321"},{"key":"e_1_3_3_4_2","unstructured":"Herceptin\u00ae (trastuzumab). Package insert. Genentech Inc. 2024."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0286"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b23-00123"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04492-6"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10387"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-025-10037-z"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00816"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzl014"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001786-200301000-00007"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3753-y"},{"key":"e_1_3_3_15_2","first-page":"2114","article-title":"Infusion of trastuzumab maintenance doses over 30\u2005min","volume":"19","author":"Bertelli G.","year":"2008","unstructured":"Bertelli G. Infusion of trastuzumab maintenance doses over 30\u2005min. Ann Oncol 2008; 19: 2114\u20132115.","journal-title":"Ann Oncol"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06521-9"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261491928","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261491928","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261491928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:16:48Z","timestamp":1790651808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261491928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":15,"alternative-id":["10.1177\/10781552261491928"],"URL":"https:\/\/doi.org\/10.1177\/10781552261491928","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"10781552261491928"}}